|
A Genetic Toolbox for the Identification and Interrogation of Tumor Cells of Origin, Propagation, and Recurrence From Patient-derived Oncogenic Drivers
|
1R33CA202900-01
|
$418,128
|
BREUNIG, JOSHUA
|
CEDARS-SINAI MEDICAL CENTER
|
|
A Nanotechnology Platform for Suicide Gene Therapy of Recurring Ovarian Cancer
|
5R01CA175318-02
|
$354,563
|
HATEFI, ARASH
|
RUTGERS, THE STATE UNIV OF N.J.
|
|
A novel miR-198 replacement therapy for pancreatic cancer
|
5R01CA183984-02
|
$473,915
|
YAO, QIZHI
|
BAYLOR COLLEGE OF MEDICINE
|
|
A Phase I Study of Intracranially Administered Carboxylesterase-Expressing Neural Stem Cells in Combination with Intravenous Irinotecan in Patients with Recurrent High Grade Gliomas
|
5R01CA198076-02
|
$618,770
|
PORTNOW, JANA
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
A Universal Approach to Personalized Adoptive T cell Therapy of Cancer
|
4R01CA168900-05
|
$332,000
|
POWELL, DANIEL
|
UNIVERSITY OF PENNSYLVANIA
|
|
Adenoviral delivery of protein-based therapeutics to the tumor microenvironment
|
5F32CA189372-02
|
$45,444
|
SMITH, SHEENA
|
UNIVERSITY OF ZURICH
|
|
Adenoviral delivery of protein-based therapeutics to the tumor microenvironment
|
5F32CA189372-02X1
|
$8,850
|
SMITH, SHEENA
|
UNIVERSITY OF ZURICH
|
|
Adoptive Cell Transfer Immunotherapy of Cancer
|
ZIA BC 010984
|
$1,726,433
|
Rosenberg, Steven
|
CCR (NCI)
|
|
Adoptive T cell Therapy for Pediatric Leukemia
|
ZIA BC 011565
|
$1,035,891
|
Fry, Terry
|
CCR (NCI)
|
|
Allogeneic T cells Transduced with an Anti-CD19 Chimeric Antigen Receptor
|
ZIA BC 011415
|
$41,944
|
Kochenderfer, James
|
CCR (NCI)
|
|
Augmenting Chimeric Antibody Receptor Directed T cell Therapy for Cancer
|
4K08CA163941-05
|
$173,772
|
MOON, EDMUND
|
UNIVERSITY OF PENNSYLVANIA
|
|
Autologous T cells Transduced with an Anti-CD19 Chimeric Antigen Receptor
|
ZIA BC 011413
|
$167,778
|
Kochenderfer, James
|
CCR (NCI)
|
|
Biology and Transplantation of the Hematopoietic Stem Cell
|
5P01CA065493-22
|
$1,914,901
|
WAGNER, JOHN
|
UNIVERSITY OF MINNESOTA
|
|
BMP4 Engineered Mesenchymal Stem Cell Therapy for Glioblastoma
|
3R01CA183827-02S1
|
$137,964
|
QUINONES-HINOJOSA, ALFREDO
|
JOHNS HOPKINS UNIVERSITY
|
|
BMP4 Engineered Mesenchymal Stem Cell Therapy for Glioblastoma
|
5R01CA183827-02
|
$333,518
|
QUINONES-HINOJOSA, ALFREDO
|
JOHNS HOPKINS UNIVERSITY
|
|
Building on the success of the adoptive immunotherapy of cancer
|
ZIA BC 010763
|
$1,579,134
|
Restifo, Nicholas
|
CCR (NCI)
|
|
Cancer Immunotherapy by Targeting A2 Adenosine Receptor
|
4R01CA111985-10
|
$214,407
|
SITKOVSKY, MICHAIL
|
NORTHEASTERN UNIVERSITY
|
|
Cancer Prevention and Treatment by Activation of a Brain-Adipocyte Axis
|
4R01CA166590-04
|
$319,550
|
CAO, LEI
|
OHIO STATE UNIVERSITY
|
|
Career Development in Pediatric and Medical Oncology
|
2K12CA076930-16A1
|
$531,466
|
BERNSTEIN, IRWIN
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Cell Production Core Facility
|
ZIC BC 011569
|
$803,455
|
Somerville, Robert
|
CCR (NCI)
|
|
Cellular biofactories for therapeutic protein synthesis in tumor microenvironment
|
5R21CA193064-03
|
$288,035
|
BHATNAGAR, PARIJAT
|
SRI INTERNATIONAL
|
|
Chronic Lymphocytic Leukemia Research Consortium
|
4P01CA081534-16
|
$3,104,311
|
KIPPS, THOMAS
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
|
Clinical management of patients on immunotherapy protocols
|
ZID BC 011578
|
$15,439
|
Klebanoff, Christopher
|
CCR (NCI)
|
|
Clinical production of viral vectors for cancer gene therapy
|
ZIC BC 010989
|
$451,117
|
Feldman, Steven
|
CCR (NCI)
|
|
Combination Gene Therapy and Th1-Th2 Therapy
|
ZIA BC 011219
|
$252,285
|
Fowler, Daniel
|
CCR (NCI)
|
|
Combination Therapy of OvCa with Oligonucleotides and Photodynamic Therapy
|
1R01CA194064-01A1
|
$84,166
|
MING, XIN
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
Combination Therapy of OvCA with Oligonucleotides and Photodynamic Therapy
|
7R01CA194064-02
|
$193,994
|
MING, XIN
|
WAKE FOREST UNIVERSITY HEALTH SCIENCES
|
|
Combining STAT3-silencing and oncolytic vaccinia virus to enhance anti-tumor therapeutic activity
|
1F32CA199981-01A1
|
$56,118
|
BYRD, DANIEL
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
|
Common hTERT Promoter Mutations Represent a Novel Therapeutic Target
|
1R21CA191663-01A1
|
$167,023
|
MILLER, DONALD
|
UNIVERSITY OF LOUISVILLE
|
|
CRLF2 signaling in B-cell acute lymphoblastic leukemia
|
2R01CA151898-06A1
|
$392,969
|
WEINSTOCK, DAVID
|
DANA-FARBER CANCER INST
|
|
CRLF2 signaling in B-cell acute lymphoblastic leukemia
|
3R01CA151898-06A1S1
|
$199,999
|
WEINSTOCK, DAVID
|
DANA-FARBER CANCER INST
|
|
Design of Oncolytic Adenovirus Conjugated with Novel Polymer for Cancer Treatment
|
4R01CA177932-04
|
$309,175
|
KIM, SUNG WAN
|
UNIVERSITY OF UTAH
|
|
Developing a Novel System for Cancer Therapy: Tumor-Targeted Inhibition of Oncogenic MicroRNAs
|
5F30CA196020-02
|
$27,876
|
SVORONOS, ALEXANDER
|
YALE UNIVERSITY
|
|
Developing inducible CRISPR to identify molecular targets in melanoma
|
5R21CA192241-02
|
$162,038
|
VANBROCKLIN, MATTHEW
|
UNIVERSITY OF UTAH
|
|
Developing novel strategies for altering the cytokine microenvironment of tumors
|
5R21CA184433-02
|
$200,318
|
FRELINGER, JOHN
|
UNIVERSITY OF ROCHESTER
|
|
Development of fully-human anti-CD30 chimeric antigen receptors
|
ZIA BC 011660
|
$125,833
|
Kochenderfer, James
|
CCR (NCI)
|
|
DF/HCC Kidney Cancer SPORE
|
5P50CA101942-12
|
$2,156,131
|
MCDERMOTT, DAVID
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
DICER1 and the Pleuropulmonary Blastoma Family Cancer Syndrome
|
2R01CA143167-06A1
|
$425,390
|
HILL, DANA
|
CHILDREN'S RESEARCH INSTITUTE
|
|
Direct coregulation of Notch1 by Zmiz1 in T-cell leukemia
|
5R01CA196604-02
|
$354,563
|
CHIANG, MARK
|
UNIVERSITY OF MICHIGAN
|
|
Disrupting tumor/bone malignant interactions with multifunctional cytokine sonodelivery
|
1R01CA196947-01A1
|
$361,974
|
FIGUEIREDO, MARXA
|
PURDUE UNIVERSITY
|
|
DNA-specific pattern recognition receptor activation following DNA electroporation
|
1R01CA196796-01A1
|
$329,919
|
HELLER, LOREE
|
OLD DOMINION UNIVERSITY
|
|
Duke SPORE in Brain Cancer
|
5P50CA190991-03
|
$2,036,564
|
SAMPSON, JOHN
|
DUKE UNIVERSITY
|
|
Dusp4 in breast cancer: tumor suppressor biology and therapeutic strategies
|
6R00CA181491-03
|
$250,586
|
BALKO, JUSTIN
|
VANDERBILT UNIVERSITY MEDICAL CENTER
|
|
Efficient Delivery of Plasmid DNA to Achieve Appropriate Transgene Expression
|
5R01CA186730-02
|
$367,893
|
HELLER, RICHARD
|
OLD DOMINION UNIVERSITY
|
|
Elucidating the role of microRNAs in the initiation of multiple myeloma
|
5R00CA172292-04
|
$248,999
|
ZHAO, JIANJUN
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
Enhancing Antitumor Immunity by Suppressing TGF-Beta Signaling in CD8+ T Cells
|
5F31CA196258-02
|
$33,695
|
PUPLAMPU-DOVE, YVONNE
|
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
|
|
Enhancing HPV-16 E6/E7 Specific Antitumor Immunity
|
4R01CA114425-10
|
$303,371
|
WU, TZYY-CHOOU
|
JOHNS HOPKINS UNIVERSITY
|
|
Enhancing Immunological Memory Using Aptamer targeted siRNA Delivery to T Cells
|
3R01CA181598-03S1
|
$100,813
|
GILBOA, ELI
|
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
|
|
Enhancing Immunological Memory Using Aptamertargeted siRNA Delivery to T Cells
|
5R01CA181598-03
|
$318,513
|
GILBOA, ELI
|
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
|
|
Enhancing T Cell Therapy of Cancer
|
4P01CA094237-14
|
$1,932,287
|
HESLOP, HELEN
|
BAYLOR COLLEGE OF MEDICINE
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|